Home > Products > CD64 & GD2 > Recombinant Anti-CD64 x Anti-GD2 Bispecific Antibody (sdAb-IgG)

Recombinant Anti-CD64 x Anti-GD2 Bispecific Antibody (sdAb-IgG)  (CAT#: BSSG-392)

Recombinant Anti-CD64 x Anti-GD2 Bispecific Antibody (sdAb-IgG) is formed by an IgG and two single domains antibodies (sdAbs). The sdAbs from an anti-GD2 antibody variable domain are respectively connected to the N terminus of the anti-CD64 IgG heavy chains or light chains to form sdAb-(H)IgG or sdAb-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors therapy.
Datasheet INQUIRY

Specifications

Targets
CD64 & GD2
Type
sdAb-IgG
Species Reactivity
Human
Application
FuncS; Promising therapeutic agent
Related Disease
Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors
Host Animal 1
Mouse
Host Animal 2
llama

Targets

Target 1
CD64
Gene ID
UniProt ID
Alternative Names
FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI
Target 2
GD2
Alternative Names
Ganglioside GD2; GD2; Ganglioside; Disialoganglioside GD2
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

Related products of "CD64 & GD2"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD64 x Anti-GD2 Bispecific Antibody (sdAb-IgG) (BSSG-392). Click the button below to contact us or submit your feedback about this product.